Global and United States Diabetes Devices and Drugs Market Report & Forecast 2022-2028

Market Analysis and Insights: Global and United States Diabetes Devices and Drugs Market
This report focuses on global and United States Diabetes Devices and Drugs market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Diabetes Devices and Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, by Type, Diabetes Devices accounting for % of the Diabetes Devices and Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Diagnostic/Clinics was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
In United States the Diabetes Devices and Drugs market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period.
Global Diabetes Devices and Drugs Scope and Market Size
Diabetes Devices and Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Diabetes Devices and Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Diabetes Devices and Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Diabetes Devices
Diabetes Drugs
Segment by Application
Diagnostic/Clinics
ICUs
Home Healthcare
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Medtronic
BD
Johnson & Johnson
Abbott Laboratories
Novo Nordisk
Bristol-Myers Squibb
DexCom
Companion Medical
GlaxoSmithKline
Glenmark Pharmaceuticals
Novartis
Roche
Sanofi
MSD
Astrazeneca
Takeda
North China Pharmaceutical Group Corporation
Huadong Medicine
Dongbao Pharmaceutical
Hisun Pharmacy
KELUN
Ginwa
Tianan Pharmaceutical